A therapeutic bovine milk exosome-siTGF-β1 drug for pulmonary fibrosis
Mediating siRNA inhibition of TGF-β1 expression by exosome vector of cow milk, solving the problem of limited effect of existing drugs for pulmonary fibrosis treatment, and effectively reducing inflammation and fibrosis in mouse models and improving survival rates. Potential treatment for pulmonary fibrosis.
Patent Information
- Application Number
- CN202310898871.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-07-21
AI Technical Summary
The existing drugs for treating pulmonary fibrosis are limited in effect, and lung transplantation lacks organ resources and has a high risk of complications, making it difficult to popularize treatments. It is necessary to explore stable and small side effects to reduce mortality and improve prognosis.
Using cow milk exosome-siTGF-β1 drug, the siRNA mediating the low expression of TGF-β1 is introduced into the exosome to form M-siTGF-β1, and is prepared by electro-transfer method, ultrasound method or modified CaCl2 method, and the tracheal atomization is given. Drugs can inhibit TGF-β1 protein expression and epithelial-mesenchymal transformation pathways, alleviate inflammatory cell infiltration and extracellular matrix deposition.
In beas-2b cells and bleomycin-induced mouse lung fibrosis models, M-siTGF-β1 effectively delivers siRNA, inhibits TGF-β1 expression, reduces inflammation and extracellular matrix deposition, and improves mouse survival, representing a A potential treatment strategy for pulmonary fibrosis.
Smart Images

Figure CN116870025B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical technology, and in particular relates to a bovine milk exosome-siTGF-β1 drug for treating pulmonary fibrosis. Background Art
[0002] Pulmonary fibrosis (PF) is a serious diffuse interstitial lung disease. Inflammatory lung diseases, inhaled particulate matter, and the use of certain drugs can all lead to PF. The pathological characteristics of PF are inflammatory cell infiltration, fibroblast proliferation, and a large amount of extracellular matrix (ECM) deposition, which ultimately lead to irreversible deformation of the lung structure. Its pathological process is almost irreversible. Once the disease occurs, the median survival time of patients is only 3 to 5 years. In recent years, due to factors such as air pollution and special pathogens, the incidence of PF has increased year by year. The main treatment drugs for PF include pirfenidone and nintedanib, but their therapeutic effects are very limited. At present, the effective means of treating pulmonary fibrosis is lung transplantation, but organ resources are scarce, the supply from donor institutions is limited, and there are risks of infection, rejection, and complications in the future. The median survival after transplantation is only 4.5 years. The high cost and the need for lifelong immunosuppressant treatment limit its promotion and use in clinical practice. During the treatment of patients with pulmonary fibrosis, if the development of lung damage can be inhibited in time and the progression of pulmonary fibrosis can be blocked, it will be of great help in reducing the degree of fibrosis damage and improving the patient's lung function. Therefore, exploring the pathogenesis of PF, determining effective treatment targets, and seeking therapeutic drugs with stable efficacy and few side effects to reduce the mortality rate and improve the prognosis of PF patients are important issues that need to be urgently addressed in today's clinical medicine and scientific research, and have far-reaching significance.
[0003] One of the most notable features of PF is the excessive deposition of ECM proteins, which causes normal tissue to be replaced by nonfunctional scar tissue. Epithelial-mesenchymal transition (EMT) is considered to be the most important process causing the development of IPF, and it is the main source of myofibroblast formation in the lungs. During pulmonary fibrosis, alveolar epithelial cells differentiate into mesenchymal-like cells under the stimulation of various fibrosis inducers, and further proliferate and differentiate into myofibroblasts, expressing the myofibroblast marker α-smooth muscle actin (α-SMA), and releasing a large amount of ECM, mainly including type I collagen. The activation and transformation of lung fibroblasts is a key step in the EMT pathway, and transforming growth factor-β1 (TGF-β1) is considered to be the most critical cell growth factor involved in this process. In addition, TGF-β1 can also directly stimulate the production of receptors for various growth factors, such as EGFR, PDGF, CTGF, etc., which play an important role in the transformation of fibroblasts and the production of ECM.
[0004] In the TGF-β superfamily, three subtypes have been identified: TGF-β1, TGF-β2, and TGF-β3. Among them, TGF-β1 plays a leading role in promoting fibrotic diseases. It is a key fibroblast activation factor with a strong profibrotic effect. In the activation process of TGF-β, mature TGF-β homodimers first bind to the homodimers of TGF-βRII with the assistance of TGF-βRIII, and then phosphorylate TGF-βRI homodimers (TGF-βRI, ALK5) under the action of the hexameric complex of TGF-β, TGF-βRII, and TGF-βI homodimers. Subsequently, TGF-βRI phosphorylates Smad2 protein in the cytoplasm and phosphorylates Smad3 protein. Finally, Smad2 / 3 translocates to the nucleus and exerts transcriptional activity under the tight binding with Smad4 protein.
[0005] Bleomycin (BLM) is a broad-spectrum chemotherapy drug used in many tumors, but clinical investigations have found that BLM can cause multi-organ fibrosis, among which PF is the most common, and its mechanism may be related to the lack of BLM hydrolase in the lungs. Researchers have found that BLM given to animals by tracheal instillation can stably cause PF in animals, and its pathological process is similar to human PF, both of which are acute / chronic inflammation leading to damage to lung epithelial cells, proliferation of lung fibroblasts, collagen deposition, and ultimately loss of alveolar structure and lung remodeling, causing loss of pulmonary ventilation / gas exchange function, and even death.
[0006] Exosomes (Exo) refer to extracellular vesicles (EVs) secreted by cells, with a diameter of about 30–150 nm. They are produced by multivesicular bodies budding into the cell to produce intraluminal vesicles targeting the plasma membrane. The process is related to the endosomal sorting complex pathway and ceramide-dependent pathway required for transport. A variety of cells can secrete exosomes under normal and pathological conditions, and exosomes naturally exist in body fluids, including blood, saliva, urine, cerebrospinal fluid and breast milk.
[0007] Exosomes are formed by lipid bilayer membranes, which contain proteins, nucleic acids, lipids and their derivatives. The proteins contained in exosomes include intraluminal proteins and transmembrane proteins, such as heat shock proteins, tetraspanins, etc. Among them, tetraspanins, especially leukocyte differentiation antigen 63 (CD63) and leukocyte differentiation antigen 81 (CD81), are commonly used specific exosome markers. The nucleic acids contained in exosomes include messenger RNA, microRNA (miRNA) and long non-coding RNA. Studies have shown that nucleic acids in exosomes are involved in many disease processes, such as tumors, cardiovascular diseases, autoimmune diseases, etc. The lipids rich in exosomes mainly include cholesterol, glycosphingolipids, sphingomyelin, phosphatidylserine, arachidonic acid, etc. These lipids are not only involved in the formation of exosomes, but also in the physiological and pathological processes of cells. Studies have shown that the most important function of exosomes is to communicate with neighboring cells through cell-cell contact. Exosomes can communicate with distant cells through secreted soluble factors (such as hormones and cytokines), and can also participate in signal transduction through electronic and chemical signals (such as nucleotides, lipids and short peptides). In addition, exosomes play a key role in maintaining tissue cell function and regulating the homeostasis of the intracellular environment, and can regulate the function of immune cells, thereby mediating immune responses.
[0008] Exosomes have unique biological properties according to their sources. Milk exosomes (M-EXO) are isolated and purified from fresh milk. They are rich in the same phospholipid bilayer membrane structure as the cell membrane, tightly wrapping specific proteins, lipids, miRNA, DNA fragments such as cytokines and growth factors, and can quickly break through the cell biomembrane barrier, accurately identify and locate cell damage, etc. M-EXO is a unique type of microbubble that is evolutionarily conserved. It maintains the integrity of the nucleic acids and proteins it contains while passing through the stomach and gastrointestinal tract. They can act locally or be transported to the circulatory system. In addition, milk exosomes are more stable than other naturally occurring exosomes, and they show excellent stability under acidic conditions and other harsh conditions. Summary of the invention
[0009] The purpose of the present invention is to provide a therapeutic bovine milk exosome-siTGF-β1 drug for pulmonary fibrosis.
[0010] Another object of the present invention is to provide a use of a bovine milk exosome-siTGF-β1 drug in the treatment of pulmonary fibrosis.
[0011] Furthermore, the preparation method of the bovine milk exosome-siTGF-β1 drug is: using bovine milk exosomes as an RNAi delivery system, introducing siRNA that mediates low expression of TGF-β1 into exosomes, and forming M-siTGF-β1 (bovine milk exosome-siTGF-β1) drug, wherein the positive chain of the siRNA sequence that mediates low expression of TGF-β1 is as shown in SEQ.ID.NO.1: CCCAAGGGCUACCAUGCCAACUUCU, and the antisense chain is as shown in SEQ.ID.NO.2: AGAAGUUGGCAUGGUAGCCCUUGGG.
[0012] Furthermore, the preparation method of the bovine milk exosome-siTGF-β1 drug is an electroporation method, comprising the following steps: mixing the bovine milk exosomes and siRNA in a 500 μL PBS solution in proportion, i.e., a 500 μL system. After mixing, incubate at 4°C for 30 minutes, and electroporate using the following method: 220V, pulse time 10ms, 3 pulses, interval time 2s. After electroporation, take out the treated sample and incubate it at 37°C for 1 hour to promote the recovery of the exosome membrane.
[0013] Furthermore, the ratio of the milk exosomes to the siRNA is 1:5.
[0014] Furthermore, the preparation method of the bovine milk exosome-siTGF-β1 drug is an ultrasonic method, comprising the following steps: bovine milk exosomes and siRNA are mixed in PBS at a ratio of 1:5 (mass / mass), 30W, 6 30-second on / off cycles, and a cooling time of 2 minutes between each cycle. After ultrasonic treatment, the solution is incubated at 37°C for 30 minutes to restore the exosome membrane.
[0015] Furthermore, the preparation method of the bovine milk exosome-siTGF-β1 drug is a modified version of the CaCl2 method, comprising the following steps: mixing siRNA with bovine milk exosomes in PBS, and then adding CaCl2 (final concentration of 100 mM). The final volume is adjusted to 500 μL using sterile PBS. The mixture is placed on ice for 30 minutes. After heat shock at 42°C for 60 seconds, the mixture is placed on ice for another 5 minutes.
[0016] The beneficial effects of the present invention are as follows: the efficacy of M-siTGF-β1 has been verified at the beas-2b cell level and in the bleomycin-induced mouse pulmonary fibrosis model. Through tracheal atomization administration, it was found that M-siTGF-β1 can effectively deliver the target siRNA to the lungs, leading to selective gene silencing, inhibiting TGF-β1 protein expression, and the epithelial-mesenchymal transition pathway (EMT). The pharmacological and efficacy results in vivo and in vitro showed that M-siTGF-β1 reduced the infiltration of inflammatory cells, reduced the deposition of extracellular matrix, and increased the survival rate of mice with pulmonary fibrosis. M-siTGF-β1 may represent a potential strategy for the treatment of pulmonary fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 :A. Encapsulation efficiency of M-EXO loaded with siRNA by electroporation, ultrasound and improved CaCl2 transfection method, B. Encapsulation efficiency of M-EXO and siRNA at different ratios by electroporation, C. Encapsulation efficiency at different voltages by electroporation;
[0018] Figure 2 :B. Changes in Exo particle size before and after atomization, C. Differences in Zeta potential before and after atomization, D. Encapsulation efficiency of Exo-encapsulated siRNA before and after atomization;
[0019] Figure 3 :Stability experiment of M-EXO under different pH conditions;
[0020] Figure 4 :A. Cell viability under different BLM concentrations, B. Expression of TGFβ1 under different BLM concentrations;
[0021] Figure 5 :Uptake of M-EXO by Beas-2b cells
[0022] Figure 6 :Effects of different drug treatment groups on the survival activity of Beas-2b cells induced by bleomycin
[0023] Figure 7 : Distribution of M-EXO in mice;
[0024] Figure 8 : Detection of TGF-β1 expression in lung tissues treated with different methods;
[0025] Fig. 9 :Changes in the status and survival time of mice treated differently;
[0026] Fig.10 :Chart of lung tissue status and lung weight under different treatments
[0027] Fig.11: Pathological staining of lung tissues treated with different methods: HE staining and Masson staining
[0028] Fig.12 :The expression level of IL-6 in different treatments
[0029] Fig.13 :A. Expression levels of E-cadherin in different treatments, B. Expression levels of Vimentin in different treatments;
[0030] Fig.14 : Expression levels of MMP2 and MMP9 in different treatments;
[0031] Fig.15 : The expression levels of ECM proteins Collagen I (involved in the formation and remodeling of fibrotic ECM in the lung), Fibronectin, α-SMA, and CTGF under different treatments. DETAILED DESCRIPTION
[0032] Example 1
[0033] Preparation and characterization of M-siTGF-β1
[0034] 1.1 Investigation of the preparation method of M-siTGF-β1
[0035] Acquisition of bovine milk exosomes
[0036] Purchased from UR53202 Milk Exosome Extract
[0037] Milk exosome extract concentration 1ug / uL
[0038] TGF-β1 sequence (5'-3'):
[0039] Justice chain: CCCAAGGGCUACCAUGCCAACUUCU
[0040] Antisense strand: AGAAGUUGGCAUGGUAGCCCUUGGG
[0041] 1) Electroporation
[0042] Milk exosomes and siRNA were mixed in 500 μL PBS solution in proportion, i.e., in a 500 μL system. After mixing, the mixture was incubated at 4°C for 30 min, and electroporated using the following method: 220 V, pulse time 10 ms, 3 pulses, and interval time 2 s. After electroporation, the treated samples were removed and incubated at 37°C for 1 h to promote the recovery of the exosome membrane.
[0043] 2) Ultrasonic method
[0044] Milk exosomes and siRNA were mixed in PBS at a ratio of 1:5 (mass / mass) at 30 W for 6 30-second on / off cycles with a 2-minute cooling time between each cycle. After sonication, the solution was incubated at 37 °C for 30 minutes to restore the exosome membrane.
[0045] 3) Improved CaCl2 method
[0046] For the modified CaCl2 method, siRNA was mixed with milk exosomes in PBS, and then CaCl2 was added (final concentration 100 mM). The final volume was adjusted to 500 μL using sterile PBS. The mixture was placed on ice for 30 minutes. After heat shock at 42°C for 60 seconds, the mixture was placed on ice for another 5 minutes.
[0047] 1.2M-siTGF-β1 characterization
[0048] 1.2.1 Exosome size and concentration
[0049] The Nanosight 3000 (NS300) uses a laser light source to illuminate the nanoparticle suspension, and with the help of a metal coating to form a completely black background, the Brownian motion of particles with scattered light can be clearly observed. For a wide distribution system, NTA can directly observe, automatically track, and calculate the particle size of each particle at the same time, and simultaneously obtain the particle size distribution information of the entire system. Combined with the scattering intensity of the particles, the NTA software can draw a three-dimensional map of the particle size, the corresponding number distribution intensity, and the scattering intensity, which can clearly distinguish samples with the same particle size but different materials.
[0050] 1.2.2 Zeta potential
[0051] The zeta potential of exosomes was detected using a nanoparticle size potential analyzer. About 800 μL of exosomes resuspended in PBS were added to the sample measurement cell for zeta potential detection.
[0052] 1.2.3 Encapsulation efficiency test of M-siTGF-β1 before and after atomization
[0053] Using the RiboGreen kit, the total RNA content and free RNA content of the samples after electroporation were determined.
[0054] The exosome samples were “demulsified” with an equal volume of 2% TritonX100 solution to obtain total RNA.
[0055] 1.3 Stability test of M-EXO under different pH conditions
[0056] To investigate the stability of M-Exo in a weakly acidic environment, M-Exo was incubated in PBS containing 10% FBS at pH 7.4 or 6.8 at 37°C for 0 h, 6 h, 12 h, 24 h, and 48 h. NTA was used to measure the particle size of M-Exo at different pH and time points.
[0057] result
[0058] 1. Preparation and characterization of M-siTGF-β1
[0059] 1.1 Investigation of the preparation method of M-siTGF-β1
[0060] First, we used three different methods to load siRNA into M-EXO: electroporation, ultrasound, and modified CaCl2 transfection. Figure 1 As shown in A, after M-EXO was loaded with siRNA, its encapsulation efficiency was 34.99%, 16.28% and 4.68% respectively. The encapsulation efficiency of electroporation was higher than that of the other two methods, and the process conditions of electroporation for siRNA encapsulation were further investigated.
[0061] The preparation process was investigated according to the electroporation method, and the encapsulation rate was used as the evaluation index. Figure 1 As shown in B, when other factors remain unchanged and only the ratio of M-EXO to siRNA is changed to 1:1, 1:5, 1:10, and 1:15, the encapsulation efficiency is significantly increased at 1:5. Therefore, the ratio of M-EXO to siRNA is selected to be 1:5.
[0062] like Figure 1 As shown in C, when other factors remain unchanged and only the voltage is changed to 100V, 160V, 220V, and 280V, the encapsulation rate increases with the increase of voltage. When the voltage is increased to 220V, it is found that the encapsulation rate has a downward trend with further increase of voltage. Therefore, the electroporation voltage is selected to be 220V.
[0063] 1.2M-siTGF-β1 characterization
[0064] First, siRNA was encapsulated into M-Exo by electroporation. Exo loaded with drug (Exo-siRNA) and Exo without drug (Exo-Con) were atomized by nebulization. NTA was used to measure the change in Exo particle size; Zeta was used to measure the change in Exo potential; Quant-iT TM RiboGreen TM The changes in encapsulation efficiency were determined by RNA Assay Kit.
[0065] like Figure 2 As shown in B, particle size: there is no difference in the size of Exo particles before and after atomization, and atomization has no effect on the Exo particle size; Figure 2 As shown in C, the Zeta potential of the exosome itself is around -5, and the potential measured after encapsulating siRNA is around -20. Free siRNA is negatively charged, and the absolute value of the potential is slightly reduced after atomization, but there is no difference. Atomization has no effect on the potential of Exo. Figure 2 As shown in D, the encapsulation efficiency of Exo-encapsulated siRNA decreased slightly before and after nebulization but there was no difference, and nebulization had no effect on the encapsulation efficiency.
[0066] 1.3 Stability test of M-EXO under different pH conditions
[0067] like Figure 3 As shown, there was no significant change in particle size when M-EXOs were incubated in phosphate-buffered saline (PBS) containing 10% fetal bovine serum (FBS) at pH 7.4 or 6.8 over 48 h, indicating that M-EXOs can maintain their intact structure in the slightly acidic extracellular pH of IPF lung tissue.
[0068] Example 2
[0069] 2. Cell experiments
[0070] 2.1 Cellular uptake of M-Exo
[0071] Beas-2b cells were cultured at 3×10 4 The cells were inoculated into 24-well plates at a density of 100 μL / well and placed in an incubator for 24 h. The original culture medium was replaced with fluorescently labeled bovine milk exosome suspension and incubated with the co-cultured cells for 1 h and 4 h. After treatment, the cells were washed 3 times with PBS and DAPI staining was used to mark the cell nucleus. Subsequently, 500 μL of 4% paraformaldehyde was added and incubated for 15 min to fix the cells. The cells were washed 3 times with PBS and imaged using a high-resolution live cell imaging system (Cytation TM , BioTek, US) observed.
[0072] 2.2 Establishment of BLM-induced cell fibrosis model
[0073] The optimal dose and time of BLM-induced cell fibrosis were screened by MTT assay for cell viability. In order to study the effect of BLM on fibrosis at the cell level, cells were plated at 5 × 10 3The cell density of cells / well was inoculated in the well plate and cultivated in the incubator for 24 hours. Beas-2b cells were treated with different concentrations of BLM (0, 0.5, 1 and 2 μg / mL), and then maintained in 100 μL of culture medium and co-cultured with cells for 24 hours. Three groups of parallels were established for each concentration, and a blank group was established at the same time, and the activity of this group was used as 100% cell viability. 10 μL of MTT solution was directly added to each group, which could be reduced by living cells after 4 hours in the incubator. The liquid was sucked off, 100-200 μL DMSO was added, the well plate was placed in an oscillator for 10 minutes, and the absorbance was measured at 490 nm.
[0074] 2.3 Determination of cell viability
[0075] Beas-2b cells were seeded at a density of 5000 cells / well in a 96-well plate. When the cells proliferated to 70%-80%, 1 μg / mL BLM (diluted with conditioned medium) was added. Ctrl group (without BLM), BLM group, M-EXO group, and BLM-EXO group were set up. After 24 hours, cell viability was detected with MTT.
[0076] result
[0077] 2.1 Effect of BLM on Beas-2b cell proliferation
[0078] In order to study the molecular mechanism of exosomes in alleviating pulmonary fibrosis, we used BLM to construct a fibrosis model at the cellular level. TGFβ1 plays a key role in the occurrence and development of fibrosis. Figure 4 As shown, we first used the expression of TGFβ1 to screen the optimal concentration of BLM to induce cell fibrosis. BLM at both 1μg / ml and 2μg / ml could induce high expression of TGFβ1. Therefore, in subsequent experiments, we chose a BLM concentration of 1μg / ml to induce Beas-2b cell fibrosis.
[0079] 2.2M-EXO can enter target cells
[0080] like Figure 5 The experimental results showed that using DIR to label bovine milk exosomes, it was observed that red-coated exosomes could be effectively absorbed by Beas-2b cells. The presence of BLM increased the uptake of bovine milk exosomes by Beas-2b cells. The uptake at 4h was greater than that at 1h, and the same was true for cells treated with BLM.
[0081] 2.3M-siTGF-β1 enhances the resistance of Beas-2b cells to BLM
[0082] In order to study the effect of M-siTGF-β1 on the expression of inflammation- and fibrosis-related molecules in the IPF cell model, Beas-2b cells were first treated with 1 μg / mL BLM for 24 h to induce a cell fibrosis model. After treatment with different drugs, cell viability was measured.
[0083] like Figure 6 The experimental results showed that BLM could significantly reduce the cell viability of Beas-2b. The addition of M-EXO, NakedsiTGF-β1 and M-siNC had no effect on the cell growth state. After the addition of M-siTGF-β1, the cell survival activity was significantly improved, indicating that M-siTGF-β1 enhanced the resistance of Beas-2b cells to the effects of BLM.
[0084] Example 3
[0085] 3. Animal Experiments
[0086] 3.1 Distribution and uptake of M-Exo in vivo
[0087] The milk exosomes were labeled by DIR and injected through atomization. In vivo images were taken using a small animal imaging system at 0h, 4h, 1day, 3days, 5days, and 7days, and tissues such as the heart, liver, lungs, kidneys, and spleen were collected. Based on the biodistribution of the DIR-labeled milk exosomes, the retention of the exosomes in the lungs was observed.
[0088] 3.2 Establishment of animal model of pulmonary fibrosis
[0089] Most of the intrapulmonary drug delivery in mice involved in previous studies was after incision, but the biggest disadvantage of this method is that the animals have poor self-control behavior, are difficult to tolerate the surgical wound, and are prone to scratching and biting the wound, which affects wound healing; at the same time, the tracheal incision is large, with a high risk of infection and high mortality, which seriously affects the accuracy of the experimental results. Therefore, after consulting a large amount of literature and multiple experimental attempts, this project decided to use mouse tracheal aerosol drug delivery to establish an in vivo model.
[0090] Forty-five 8-week-old male C57BL / 6 mice were randomly divided into 6 groups, including control group (5 mice), bleomycin (BLM)-treated group (8 mice), BLM+M-EXO group (8 mice), BLM+Naked siTGF-β1 (8 mice), BLM+M-siNC (8 mice) and BLM+M-siTGF-β1 (8 mice). On day 0, 1.5 mg / kg BLM solution dissolved in saline was injected intratracheally (50 μL / mouse), and the control group mice were injected with 50 μl of saline in the same way. Starting from the 14th day of modeling, mice in the BLM+M-EXO group were nebulized with M-Exo in the trachea, mice in the BLM+Naked siTGF-β1 group were nebulized with Naked siTGF-β1 in the trachea, mice in the BLM+M-siNC group were nebulized with M-siNC in the trachea, mice in the BLM+M-siTGF-β1 group were nebulized with M-siTGF-β1 in the trachea, and the BLM group was nebulized with an equal amount of non-functional saline. The weight and mortality of the mice were recorded during the experiment. On the 28th day, the mice were killed by cervical dislocation and the mouse lung tissues were collected for subsequent experiments. 3.3 RNA extraction
[0091] 1. Cells: After the 6-well plate is full of cells, place it on ice, remove the culture medium, wash twice with PBS, add 500 μl trizol to each well, blow the cells off by pipetting up and down, and add them to a clean 1.5 ml RNase-free centrifuge tube.
[0092] Tissue: Weigh 0.1 g of tissue and place it in a 1.5 ml centrifuge tube. Add 200 μl of trizol. Cut the tissue into small pieces with scissors. Grind the tissue with a grinding rod. Add 800 μl of trizol to make up to 1 ml.
[0093] 2. Add 200 μl of chloroform (half the number of cells) to the tissue, shake vigorously for 15 seconds, and leave at room temperature for 3 minutes.
[0094] 3. Centrifuge at 12000rpm and 4℃ for 15min. It will be divided into three layers: upper RNA layer, middle layer and lower protein layer. Take the supernatant (about 500μl) into a clean 1.5ml RNase-free centrifuge tube.
[0095] 4. Add 500 μl isopropanol (half the volume of cells) to precipitate RNA, mix well, and leave at room temperature for 10 min.
[0096] 5. Centrifuge at 12000rpm, 4℃ for 10min.
[0097] 6. Discard the supernatant, add 1 ml of 80% ethanol, and wash the RNA by inverting.
[0098] 7. Centrifuge at 12000rpm, 4℃ for 5min.
[0099] 8. Pour off the supernatant and absorb as much residual ethanol as possible. Leave at room temperature for 3 minutes to allow the residual ethanol to evaporate. Add appropriate amount of DEPC water to dissolve RNA (20-40 μl for tissues / 10 μl for cells).
[0100] 9. Check the integrity of the extracted RNA samples by agarose gel electrophoresis.
[0101] 10. Use NanoDrop2000 to check the concentration and quality of the extracted RNA samples.
[0102] 3.4 RT reaction
[0103] Total RNA was extracted by Trizol according to the manufacturer's instructions. The Evo M-MLV RT Kit with gDNA Clean for qPCR II kit used in the reverse transcription experiment was from Accurate Biotechnology.
[0104] (1) Remove genomic DNA. The system is as follows:
[0105]
[0106] After mixing 10 μl of the solution, place it in a PCR instrument at 42°C for 2 minutes and then temporarily store it at 4°C.
[0107] (2) Reverse transcription, the system is as follows:
[0108]
[0109] After mixing 20 μl of the solution, place it in a PCR instrument, react at 37°C for 15 minutes, react at 85°C for 5 seconds, and temporarily store at 4°C. Store the reverse transcribed cDNA sample at -20°C.
[0110] 3.5qPCR (1)
[0112] Primer sequences used for qRT-PCR
[0113]
[0114]
[0115] (2) Fluorescence quantitative PCR reaction system is as follows:
[0116]
[0117]
[0118] (3) Fluorescence quantitative PCR reaction procedure
[0119] 1) 95℃10min
[0120] Relative expression, Excel and GraphPad Prism were used for data processing and analysis. The relative expression of genes was calculated using the 2^(-ΔΔCT) method.
[0121] 3.6 Total protein extraction
[0122] (1) Add PMSF (99:1) to RIPA lysis buffer and prepare it before use.
[0123] (2) Tissue samples: Take an appropriate amount of tissue (15-20 mg) and place it in a 1.5 ml EP tube on ice. Add 300 μl RIPA, chop the sample with scissors, and grind it with a homogenizer on ice.
[0124] (3) Place the EP tube on ice for 20 min and then centrifuge at 4°C and 12,000 rpm for 10 min.
[0125] (4) Carefully transfer the supernatant after centrifugation to a new EP tube and add loading buffer to mix.
[0126] (5) Boil the sample in boiling water for 10 minutes to denature the protein.
[0127] (6) Mix thoroughly by inversion and centrifuge moderately at room temperature, then store in a -80°C refrigerator for later use.
[0128] 3.7 Western Blot
[0129] (1) Glue preparation: Prepare 10% polyacrylamide gel separation gel, pour it into the middle of the gel plate, add anhydrous ethanol to press the gel. After the separation gel solidifies, pour out the anhydrous ethanol, add concentrated gel, and insert the comb.
[0130] (2) Electrophoresis: After the concentrated gel has solidified, add 10 μg of protein sample into the loading well and perform electrophoresis at a constant current of 30 mA.
[0131] (3) Transfer: After electrophoresis, remove the gel, activate the PVDF membrane in anhydrous methanol, and place it on the transfer clip in the order of blackboard-sponge-filter paper-gel-PVDF membrane-filter paper-sponge-whiteboard. Insert the transfer clip into the transfer tank and transfer the membrane at a constant current of 300 mA for one hour in ice.
[0132] (5) Blocking: After transfer, place the PVDF membrane in a blocking solution (5% skimmed milk powder) for one hour.
[0133] (6) Primary antibody incubation: Use TBST to rinse the blocked PVDF membrane, cut out the approximate band where the protein is located according to the location of the marker, and incubate it in the diluted primary antibody at 4°C overnight.
[0134] (7) Rinse the PVDF membrane with TBST three times, 10 minutes each time.
[0135] (8) Secondary antibody incubation: Place the PVDF membrane in the diluted secondary antibody and incubate for one hour.
[0136] (7) Rinse the PVDF membrane again with TBST for three times, each time for 15 minutes.
[0137] (8) Add an appropriate amount of ECL luminescent liquid (A:B=1:1) on the membrane and expose it on a chemiluminescence imager. The subsequent results are analyzed and processed using ImageJ and Excel.
[0138] 3.8 Tissue specimen collection
[0139] The mice in each group were killed 28 days after surgery and tissue specimens were collected.
[0140] (1) Weigh and record the weight of the mice, and then kill them by cervical dislocation.
[0141] (2) The mouse was fixed in a supine position on the animal experimental operating table, the chest wall fur of the mouse was cut along the anterior midline, the surface muscles of the chest wall were extracted with forceps, and the diaphragm and bilateral ribs were cut with scissors to expose both lungs;
[0142] (3) Sampling: Use ophthalmic scissors to completely peel off the mouse lung tissue and place it in a culture dish filled with physiological saline. Rinse off the blood remaining on the surface and record the lung weight.
[0143] (6) Specimen collection: Pathological staining specimens were stored in 1.5 ml centrifuge tubes containing 4% paraformaldehyde; RNA tissue samples were placed in 1.5 ml RNase-free centrifuge tubes; Western Blot specimens were placed in 1.5 ml ordinary centrifuge tubes, and experimental equipment was organized.
[0144] (7) Specimen storage: Pathological staining specimens should be stored at room temperature or 4°C; RNA tissue samples and Western Blot specimens should be stored at -80°C after collection.
[0145] 3.9 HE staining
[0146] The left lung of the mouse was fixed in 4% paraformaldehyde for 24 hours, and the 1 / 3 tissue in the middle of the left lobe of the mouse lung was taken out and placed in a tissue embedding box, rinsed with tap water, dehydrated in a cylinder, immersed in wax and embedded; then sliced with a thickness of 5μm. The prepared paraffin sections were dewaxed and rehydrated in a cylinder in turn; finally, the rehydrated sections were subjected to corresponding tissue staining.
[0147] Paraffin sections are routinely dewaxed and put into water: xylene I, II, and III for 10 minutes each → 100% alcohol I and II for 5 minutes each → 95% alcohol I and II for 5 minutes each → 80% alcohol for 5 minutes → 70% alcohol for 5 minutes each → immerse in PBS and wash once for about 15 seconds, then they can be used for staining.
[0148] Hematoxylin staining: Add hematoxylin dye to the staining jar, immerse for 5-15 minutes (7 minutes), and rinse with water for 1 minute.
[0149] Differentiation and blueing: After hematoxylin staining, immerse in 1% hydrochloric acid alcohol (1mL hydrochloric acid + 99mL 75% alcohol) for 2-5s. Differentiate until the tissue turns red, and rinse with running water until the water drops clear.
[0150] Eosin staining: Immerse the blued slide in an eosin staining jar for 2-3 minutes. Rinse with running water until clear.
[0151] Dehydration and transparency: water washing → 95% alcohol for 10s → 95% alcohol for 10s → 100% alcohol for 10s → 100% alcohol for 10s → xylene 3 times, 30s each time.
[0152] Sealing: Add a drop of neutral gum on the dehydrated and transparent glass slide, then cover it with a cover slip, air-dry it in a fume hood for one day, and scan under a microscope.
[0153] 3.10 Masson staining
[0154] Paraffin sections were routinely dewaxed to water, and the sections were placed in Bouin solution and mordanted for 2 hours, then rinsed under running water until the yellow color of the sample on the sections disappeared; immersed in lapis lazuli blue staining solution for 3 minutes and then rinsed with water; immersed in hematoxylin staining solution for 3 minutes and then rinsed with water; differentiated in acidic ethanol for about 30 seconds, rinsed with running water for differentiation and blueing for 10 minutes; immersed in Ponceau red staining solution for about 10 minutes and then rinsed with water; the sections were placed in phosphomolybdic acid solution for about 10 minutes; immersed in aniline blue staining solution for 5 minutes; treated in weak acid solution for 2 minutes; quickly dehydrated with 95% ethanol, dehydrated with anhydrous ethanol 3 times, each time for 10 seconds; transparentized with xylene 3 times, each time for 1 minute; and sealed with neutral gum for microscopic examination.
[0155] Results Analysis
[0156] The therapeutic effect and mechanism of M-siTGF-β1 on PF
[0157] 3.1 Tracheal atomization M-EXO is delivered to the lungs
[0158] like Figure 7 As shown, we further tracked the distribution of M-EXO labeled with the lipophilic tracer DiR, which exhibits an ideal fluorescent signal for in vivo imaging by incorporation into the cell membrane. Mice were anesthetized and then DiR-labeled M-EXO was delivered by nebulization. Images of the whole body and major organs were captured at designated time points. DiR fluorescence was only observed in the lungs after nebulization of M-EXO, and the fluorescent signal gradually weakened after day 3, so subsequent experiments were administered twice a week.
[0159] 3.2 Establishment of PF mouse model
[0160] To investigate the therapeutic effect of M-siTGF-β1 in BLM-induced idiopathic pulmonary fibrosis, we induced the mouse PF model by intratracheal injection of BLM (1.5 mg / kg) and administered M-siTGF-β1 by intratracheal aerosolization on the 14th day. The mice were killed on the 28th day and their lung tissues were obtained to detect the expression of TGF-β1.
[0161] like Figure 8 As shown, the expression level of TGF-β1 in the control group, BLM group, BLM+M-EXO group, BLM+NakedsiTGF-β1 group, BLM+M-siNC group, and BLM+M-siTGF-β1 treatment group was detected by qRT-PCR. The results of qRT-PCR showed that BLM could rapidly induce high expression of TGF-β1, and the expression of TGF-β1 was significantly decreased after treatment with M-siTGF-β1. BLM successfully induced pulmonary fibrosis in mice, and the PF mouse model of M-siTGF-β1 was successfully established.
[0162] 3.3 Effect of M-siTGF-β1 on the general condition of PF model mice
[0163] like Fig. 9 To further observe whether M-siTGF-β1 has the effect of treating BLM-induced PF, we observed the general status of mice. The results showed that the mice in the Control group had normal activities, shiny hair and normal breathing rate; the mice in the BLM group had reduced activities, their hair lost luster and their breathing rate increased compared with the Control group. The status of mice in the BLM+M-EXO group, BLM+Naked siTGF-β1 group, and BLM+M-siNC group was similar to that of the BLM group. The situation in the BLM+M-siTGF-β1 treatment group gradually improved, but it was still worse than that in the Control group.
[0164] The results of the weight changes of mice showed that the weight of the mice in the Control group kept rising steadily; the weight of the mice in the BLM group kept decreasing due to tracheal atomization of bleomycin; compared with the BLM group, BLM+M-EXO group, BLM+Naked siTGF-β1 group, and BLM+M-siNC group, the weight of the mice in the BLM+M-siTGF-β1 group began to increase slowly after the administration of M-siTGF-β1, but was lighter than that of the mice in the Control group. At the end of the experiment, the weight of the mice in the BLM+M-siTGF-β1 group decreased the least compared with the initial weight, which suggests that BLM can inhibit the increase in the weight of mice, and M-siTGF-β1 can improve the weight suppression of mice caused by BLM.
[0165] Bleomycin-induced fibrosis mice died early in the PBS-treated group. In contrast, mice treated with M-siTGF-β1 at 1.5 mg / kg siRNA had the latest death and the highest final survival rate during the entire experimental period, indicating that M-siTGF-β1 improved the overall survival rate of bleomycin-induced fibrosis mice.
[0166] like Fig.10 As shown in the figure, the mouse model was killed by cervical dislocation, and the mouse lung tissue was separated. The volume and color of the lung tissue were observed by naked eyes. The results showed that the volume of the lung tissue of the mice in the Control group was relatively normal and the color was light pink; the lungs of the mice in the BLM group were severely congested, and their volume was slightly smaller than that of the Control group; compared with the BLM group, BLM+M-EXO group, BLM+Naked siTGF-β1 group, and BLM+M-siNC group, the congestion state of the mice in the BLM+M-siTGF-β1 group was significantly improved, and its volume was between the Control group and the BLM group. In addition, we also measured the weight of the lungs and found that after 28 days of BLM induction, the weight of the lungs in the BLM+M-siTGF-β1 group was significantly reduced compared with the BLM group. The results suggest that M-siTGF-β1 can improve the injured congestion of the lung tissue of the BLM-induced PF model mice, but whether it is through inhibiting the process of pulmonary fibrosis needs further study.
[0167] Effects of 3.4M-siTGF-β1 on lung tissue pathology in PF model mice
[0168] To evaluate whether M-siTGF-β1 could improve BLM-induced idiopathic pulmonary fibrosis in mice, C57BL / 6 mice were nebulized with M-siTGF-β1 on the 14th day after tracheal injection of bleomycin, and the lung tissues sampled on the 28th day were observed for histopathological changes in the mouse lungs by H&E, Masson's, and Sirius red staining.
[0169] like Fig.11 As shown in the figure, in the Control group, the alveolar tissue of mice was basically normal, and no pathological changes were observed under the optical microscope; the BLM group showed morphological damage, characterized by hemorrhage in some lobes and alveoli, interstitial edema, and inflammatory cell infiltration in the lobes; the BLM+M-EXO group, BLM+Naked siTGF-β1 group, and BLM+M-siNC group were similar to the BLM group; in the BLM+M-siTGF-β1 group, bleomycin-induced tissue damage was significantly alleviated, with only a small amount or no inflammatory cell infiltration. The results showed that M-siTGF-β1 can alleviate bleomycin-induced lung tissue pathological damage.
[0170] Effects of 3.5M-siTGF-β1 on inflammatory factors in PF model mice
[0171] The above results show that M-siTGF-β1 can reduce fibrosis and improve lung tissue pathological damage in bleomycin-induced PF mice, but its mechanism of action is not clear. The lung tissue pathological damage of PF is mainly mediated by the infiltration of proinflammatory cytokines. Therefore, in order to understand whether M-siTGF-β1 can affect the production of inflammatory cytokines in PF model mice, we conducted the following study.
[0172] like Fig.12 As shown, the mouse lung tissue was isolated, and the expression level of IL-6 was detected by q RT-PCR. The results showed that compared with the Control, the expression level of IL-6 in the BLM group was significantly increased; compared with the BLM group, the expression level of IL-6 in the BLM+M-EXO group, BLM+NakedsiTGF-β1 group, and BLM+M-siNC group decreased slightly, and the BLM+M-siTGF-β1 group decreased significantly. The results showed that M-siTGF-β1 can reduce the secretion of inflammatory cytokines in mice induced by BLM, thereby reducing the inflammatory response of lung tissue and improving pulmonary fibrosis.
[0173] Effects of 3.6M-siTGF-β1 on the expression of EMT and fibrosis-related molecules in PF model mice
[0174] In vitro studies have shown that M-siTGF-β1 can affect the secretion of proinflammatory cytokines in BLM-induced mice, thereby reducing the inflammatory response in lung tissue and improving pulmonary fibrosis. In vitro studies have confirmed that M-siTGF-β1 can affect the expression of EMT and pulmonary fibrosis-related molecules in PF cell models. Therefore, in order to further explore the effect of TGF-β1 siRNA silencing on the EMT of BLM-induced pulmonary fibrosis in mice, we detected the expression of epithelial cell markers (E-cadherin), mesenchymal cell markers (Vimentin) and fibrosis-related molecules Collagen I, Fibronectin, α-SMA, and CTGF at the mRNA level.
[0175] like Fig.13 As shown, first, we detected the expression level of epithelial cell marker E-cadherin. The results showed that BLM effectively reduced the expression of E-cadherin in mouse lung tissue, while TGF-β1 siRNA gene silencing could restore most of the E-cadherin expression. This suggests that BLM may induce epithelial cell activation, and TGF-β1 gene silencing can inhibit epithelial cell activation induced by BLM.
[0176] We then detected the expression level of the interstitial cell marker Vimentin. The expression level was detected by q RT-PCR at the mRNA level. The results showed that BLM effectively increased the expression of Vimentin in mouse lung tissue, while M-siTGF-β1 could reduce the expression of Vimentin. This suggests that BLM may induce the generation of interstitial cells, while M-siTGF-β1 can inhibit the generation of interstitial cells induced by BLM.
[0177] It is described that MMP2 and MMP9, known as gelatinase A and gelatinase B, are usually upregulated during fibrosis, which can damage the basement membrane and induce lung tissue remodeling and alveolar thickening by degrading type IV collagen, leading to pulmonary fibrosis. Here, the expression levels of MMP2 and MMP9 were evaluated by q PCR analysis. Fig.14 As shown, the expression of MMP2 and MMP9 was significantly upregulated in BLM-treated mice compared with control mice. Treatment with M-siTGF-β1 significantly inhibited BLM-mediated MMP2 and MMP9 expression.
[0178] Finally, we detected the expression levels of fibrosis-related molecules ECM protein Collagen I (involved in the formation and remodeling of fibrotic ECM in the lung), Fibronectin, α-SMA, and CTGF. First, qRT-PCR was used to detect their expression levels at the mRNA level, such as Fig.15As shown, the results showed that the BLM group effectively increased the expression of collagen I, Fn, α-SMA, and CTGF in mouse lung tissue, while M-siTGF-β1 could reduce the expression of collagen I, Fn, α-SMA, and CTGF. This suggests that BLM may induce the formation of ECM, while M-siTGF-β1 can inhibit the formation of ECM induced by BLM.
Claims
1. A method for preparing a pulmonary fibrosis therapeutic bovine milk exosome-siTGF-β1 drug, characterized in that: Using bovine milk exosomes as a siRNA delivery system, siRNA that mediates low expression of TGF-β1 is introduced into exosomes to form M-siTGF-β1, i.e. bovine milk exosomes-siTGF-β1 drug, wherein the positive chain of the siRNA sequence that mediates low expression of TGF-β1 is shown in SEQ.ID.NO.1, and the antisense chain is shown in SEQ.ID.NO.
2.
2. The method for preparing the milk exosome-siTGF-β1 drug according to claim 1, characterized in that: The preparation method of the bovine milk exosome-siTGF-β1 drug is an electroporation method, comprising the following steps: mixing the bovine milk exosomes and siRNA in proportion in 500 μL of PBS solution, i.e., in a 500 μL system; incubating at 4°C for 30 minutes after mixing, and electroporating using the following method: 220V, pulse time 10 ms, 3 pulses, and an interval time of 2 s; after electroporation, taking out the treated sample and incubating it at 37°C for 1 hour to promote the recovery of the exosome membrane.
3. The method for preparing the milk exosome-siTGF-β1 drug according to claim 2, characterized in that: The ratio of the milk exosomes to the siRNA is 1:1, 1:5, 1:10 or 1:
15.
4. The method for preparing the milk exosome-siTGF-β1 drug according to claim 1, characterized in that: The preparation method of the bovine milk exosome-siTGF-β1 drug is an ultrasonic method, comprising the following steps: bovine milk exosomes and siRNA are mixed in PBS at a mass ratio of 1:5, 30W, 6 30-second on / off cycles, and a cooling time of 2 minutes between each cycle; after ultrasonic treatment, the solution is incubated at 37°C for 30 minutes to restore the exosome membrane.
5. The method for preparing the milk exosome-siTGF-β1 drug according to claim 1, characterized in that: The preparation method of the bovine milk exosome-siTGF-β1 drug is a modified CaCl2 method, comprising the following steps: mixing siRNA and bovine milk exosomes in PBS, and then adding CaCl2 to a final concentration of 100 mM; adjusting the final volume to 500 μL using sterile PBS; placing the mixture on ice for 30 minutes; and after heat shock at 42°C for 60 seconds, placing the mixture on ice for another 5 minutes.
6. Use of the drug prepared by the method for preparing the bovine milk exosome-siTGF-β1 drug according to any one of claims 1 to 5 in preparing a drug for treating pulmonary fibrosis.
